Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral formulation for oral use. It selectively antagonizes L‑type calcium channels in cerebral vessels, helping to prevent neurological deficits caused by cerebral vasospasm after subarachnoid hemorrhage.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialized cerebral vasodilator for qualified healthcare providers through regulated distribution channels and strict quality controls across multiple regions.

Nimodipine is used in the management of cerebrovascular conditions, primarily targeting cerebral vasospasm.

- Subarachnoid hemorrhage (SAH): prevents delayed cerebral ischemia and associated neurological deficits. - Cerebral vasospasm: reduces vessel narrowing to maintain cerebral blood flow. - Neurological deficits after SAH: lowers incidence of stroke‑like complications.

Nimodipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Hypotension: mild blood‑pressure reduction. - Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or angioedema. - Bradycardia: unusually slow heart rate. - Seizures: infrequent neurologic episodes.

When prescribing Nimodipine, clinicians should consider several safety measures.

- Renal impairment: monitor renal function as drug elimination may be affected. - Hepatic dysfunction: use caution; dose adjustment may be required. - Concomitant antihypertensives: observe for additive blood‑pressure lowering. - Elderly patients: start at lower dose and watch for orthostatic symptoms. - Pregnancy and lactation: avoid unless benefits clearly outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations. - Co‑administration with other calcium channel blockers: risk of additive hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): heightened hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Beta‑blockers: monitor for excessive blood‑pressure reduction. - Diuretics: watch for electrolyte disturbances and volume depletion.